Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
564-05-004 ISMRM Abstract

Associations between Cytokines and Multiparametric MRI biomarkers of Metabolic Disease Risk in Pre-pubertal Mexican Boys

Primary: Acquisition & Reconstruction - Quantitative Imaging: relaxometry, multi-parametric, MR Fingerprinting, and synthetic MRI
Secondary: Body - Liver
564-05-004 · The qMRI Variety Show: A Little Bit of Everything · Wednesday, 13 May, 4:00 PM–4:55 PM · Digital Posters Row E
Keywords: MASLD Multiparametric quantitative MRI Noninvasive metabolic imaging Corrected T1 Cytokines
Accepted
Elizabeth Shumbayawonda1, Megh Utsav1, Benito de Celis Alonso2, Briseida López-Martínez3,4, Armando Vilchis-Ordoñez3,5, Silvia Hidalgo-Tobon3,6, Jimmy Bell7, Po-Wah So8
1Perspectum, Oxford, United Kingdom
2Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
3Children’s Hospital of Mexico Federico Gómez, Mexico
4Synlab Mexico, Mexico
5CIBIOR IMSS, Mexico
6Metropolitan University of Mexico, Mexico
7University of Westminster, London, United Kingdom
8Institute of Psychiatry, Psychology, & Neuroscience, King’s College London, London, United Kingdom
Presenting Author: Matthew Robson

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Corey KE, Nakrour N, Bethea ED, Shay JE, Andersson KL, Bhan I, et al. Real-World Assessment of Liver Corrected T1 and Magnetic Resonance Elastography in Predicting Liver Disease Progression. Liver Int. 2025 Sep;45(9):e70280. doi: 10.1111/liv.70280. [doi]
2. Jayaswal, A.N.A., Levick, C., Selvaraj, E.A., Dennis, A., Booth, J.C., Collier, J., et al., Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver Int, 2020. 40(12): p. 3071-3082. doi: 10.1111/liv.14625 [doi]
3. Tacke, F., EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 2024. 81(3): p. 492 - 542. doi: 10.1016/j.jhep.2024.04.031 [doi]
4. de Celis Alonso, B., Shumbayawonda, E., Beyer, C., Hidalgo-Tobon, S., Lopez-Martinez, B., Dies-Suarez, P., et al., Liver magnetic resonance imaging, non-alcoholic fatty liver disease and metabolic syndrome risk in pre-pubertal Mexican boys. Sci Rep, 2024. 14(1): p. 26104. doi: 10.1038/s41598-024-77307-8 [doi]
5. Kang J, Postigo-Fernandez J, Kim K, Zhu C, Yu J, Meroni M, et al. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis. JCI Insight. 2023 Feb 8;8(3):e165369. doi: 10.1172/jci.insight.165369. [doi]
6. Weng SY, Wang X, Vijayan S, Tang Y, Kim YO, Padberg K, et al. IL-4 Receptor Alpha Signaling through Macrophages Differentially Regulates Liver Fibrosis Progression and Reversal. EBioMedicine. 2018 Mar;29:92-103. doi: 10.1016/j.ebiom.2018.01.028. [doi]
7. Annadurai P, Isaac AE. Unveiling the role of IL7R in metabolism-associated fatty liver disease leading to hepatocellular carcinoma through transcriptomic and machine learning approaches. Discov Oncol. 2025 May 23;16(1):873. doi: 10.1007/s12672-025-02638-5. [doi]
8. Jönsson C, Ma'ayeh S, Zhang B, Kechagias S, Liljeblad M, Nasr P, et al. Vascular endothelial growth factor A, a potential non-invasive biomarker for metabolic dysfunction-associated steatotic liver disease progression. Clin Biochem. 2025 Jun;137:110920. doi: 10.1016/j.clinbiochem.2025.110920. [doi]
9. Andersson A, Kelly M, Imajo K, Nakajima A, Fallowfield JA, Hirschfield G, et al. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis. Clin Gastroenterol Hepatol. 2022 Nov;20(11):2451-2461.e3. doi: 10.1016/j.cgh.2021.09.041. [doi]
10. Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, et al. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023 Apr;616(7958):747-754. doi: 10.1038/s41586-023-05857-4. Epub 2023 Apr 12. Erratum in: Nature. 2023 Jul;619(7970):E47. doi: 10.1038/s41586-023-06375-z. [doi]
11. Marra, F. and Tacke, F., Roles for chemokines in liver disease. Gastroenterology, 2014. 147(3): p. 577-594 e1. doi: 10.1053/j.gastro.2014.06.043 [doi]
12. Krenkel, O. and Tacke, F., Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol, 2017. 17(5): p. 306-321. doi: 10.1038/nri.2017.11. [doi]
13. Lefere, S., Devisscher, L., and Geerts, A., Angiogenesis in the progression of non-alcoholic fatty liver disease. Acta Gastroenterol Belg, 2020. 83(2): p. 301-307. PMID: 32603050. [pmid]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/564-05-004